Buscopan in Patients Undergoing IVF/Intracytoplasmic Sperm Injection Treatment

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

675 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-05-30

Study Completion Date

2024-09-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To determine if the use of Buscopan in patients undergoing IVF/ICSI treatment with high uterine contraction frequency prior to embryo transfer has a higher live birth rate.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Indomethacin Prior to Difficult Embryo Transfer is it a Solution?

NCT03533803

Difficult Embryo Transfer

COMPLETED PHASE3

Benefits of Hysteroscopy Prior to Performing a Cycle of in Vitro Fertilization/Intracytoplasmic Sperm Injection

NCT03173404

Sterility

COMPLETED NA

Role of Aromatase Inhibitor to Enhance Ovulation in Poor Responder During Induction With Short Antagonist Protocol in Cases of ICSI

NCT02741154

Infertility Indicated for ICSI

COMPLETED PHASE4

Routine Hysteroscopy in IVF/ICSI Cycles in Patients With Primary Unexplained Infertility

NCT02416596

Primary Infertility Unspecified Infertility Ovarian Hyperstimulation +1 more

UNKNOWN NA

Efficacy and Safety of Medication Used to Stimulate Ovulation

NCT02715336

IVF Cycle Ovarian Stimulation Egg Retrieval +3 more

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

IVF Intracytoplasmic Sperm Injection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

A prospective double blinded randomized controlled trial

Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

double blinded to the randomization list

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

treatment group

20mg Buscopan intravenous will be given 5 minutes prior to embryo transfer

Group Type ACTIVE_COMPARATOR

Buscopan 20 milligrams/ML Injectable Solution

Intervention Type DRUG

cases will be randomized to Buscopan group or Normal Saline group, injection will be given 5 minutes prior to embryo transfer

control group

2ml Normal Saline intravenous will be given 5 minutes prior to embryo transfer

Group Type PLACEBO_COMPARATOR

Buscopan 20 milligrams/ML Injectable Solution

Intervention Type DRUG

cases will be randomized to Buscopan group or Normal Saline group, injection will be given 5 minutes prior to embryo transfer

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Buscopan 20 milligrams/ML Injectable Solution

cases will be randomized to Buscopan group or Normal Saline group, injection will be given 5 minutes prior to embryo transfer

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Normal Saline

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\- Women undergoing embryo transfer in either fresh or frozen cycles

Exclusion Criteria

* Women aged \> 42 years old
* Women with factors which will affect uterine contractility
* congenital uterine anomaly
* acquired uterine pathology such as myoma \>5cm, adenomyosis \>5cm or endometrial polyp
* Women with presence of hydrosalpinx
* Women undergoing pre-implantation genetic test in IVF cycles
* History of allergy to misoprostol , Buscopan® or same group of drug
* Contraindication to the use of Buscopan® e.g. glaucoma, myasthenia gravis, tachycardia, megacolon
* Women who are on other smooth muscle relaxant other than Buscopan®

Maximum Eligible Age

42 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No